What is the expected relative risk of macular degeneration for lutein-treated participants versus placebo-treated participants in the proposed study? 

Suppose for the sake of simplicity that the incidence of macular degeneration is 1% per year among people65+ years of age in the therapeutic range (≥10 mg/dL) and 2% per year among people 65+ years of age with lower levels of lutein (< 10 mg/dL).